Palisade Bio Shares Surge On Positive Preclinical Data For PALI-2108
Palisade Bio, Inc. (PALI) saw a 88% increase in its stock on Monday following the announcement of positive preclinical data for its main asset, PALI-2108, at the Crohn's & Colitis Congress on January 25-27, 2024.
Source: rttnews.com